World Trade day order Pharmaceutical (Jiangsu) Co., Ltd. is located in the Yellow Sea, adjacent to the national red-crowned crane nature reserve. Its predecessor belongs to Fangqiang Farm in Jiangsu Province, and the factory name is Fangqiang Pharmaceutical Factory in Jiangsu Province. Founded in 1970, it was renamed as Jiangsu Fangqiang Pharmaceutical Factory Co., Ltd. in 2007 with a registered capital of12 million yuan. After several years of reform and innovation, the company turned losses into profits. In order to develop better and faster and take the road of collectivization and specialization, the company reorganized with Beijing World Trade day order Biotechnology Co., Ltd. at the end of 20 1 1 to become its wholly-owned subsidiary, and its name was changed to World Trade day order Pharmaceutical (Jiangsu) Co., Ltd.
Our company has gathered a large number of high-quality management, technology and R&D talents, which are market-oriented and supported by technology, attach importance to the improvement of production technology and the research and development of new products, and carry out production and management in strict accordance with GMP requirements.
World Trade day order Pharmaceutical Co., Ltd. has 55 varieties and 75 specifications, including tablets, capsules, injections and granules. Among them, pantoprazole sodium enteric-coated tablets were launched in May of 20 1 1 year, mainly used to treat gastric and duodenal ulcers. They are the substitute products of omeprazole, and have received good response after entering the market. Others include terazosin hydrochloride capsules, levofloxacin hydrochloride capsules and azithromycin capsules.
After ten years, our company spent RMB 300 million to obtain the clinical approval of the national first-class genetic biological drug "One Needle Connect" in June, 201. This is the latest third-generation thrombolytic drug for rescuing acute myocardial infarction by gene recombination, which is used for thrombolytic treatment of acute st-segment elevation myocardial infarction. The product was listed by Genentech in the United States in 2000, and then in Europe, Japan and Canada. After years of clinical application, its efficacy and safety have been widely verified. The production of "One Needle Connect" will change the backward situation of clinical thrombolytic drugs in China, make our thrombolytic drugs reach the world leading level, and fundamentally solve the limitations of interventional therapy (stent). Making the treatment concept of "dissolving first, then supporting" become a reality, saving pre-hospital life and treating patients with acute myocardial infarction in time in the vast number of small and medium-sized hospitals in China has become a milestone in changing the treatment field of acute myocardial infarction in China.
Adhering to the corporate philosophy of "caring for health and caring for all beings", the company has always adhered to the business principle of "quality first, honesty first, hand in hand and win-win cooperation", and gradually developed into a high-tech, high-input, pollution-free, low-energy and high-return gene drug, adopting the most advanced pharmaceutical technology today, and developing the most cutting-edge pharmaceutical products in the contemporary era, making greater contributions to the implementation of human health projects.
Legal Representative: Zhang Huijun.
Date of establishment:1979-11-20.
Registered capital: 30 million yuan.
Location: Jiangsu Province
Unified social credit code: 91320 9821407081740.
Operating conditions: In operation.
Industry: manufacturing industry
Company type: limited liability company (sole proprietorship)
English name: Jiangsu Fangqiang Pharmaceutical Factory Co., Ltd.
Staff size: 100-500 people.
Enterprise Address:No. Wuyi Road 1, High-tech Zone, Dafeng District, Yancheng
Scope of business: manufacture of tablets, hard capsules, granules and therapeutic biological products (recombinant human tissue plasminogen activator for injection). (Projects subject to approval according to law can only be operated after approval by relevant departments)